Lably
Skip to content

Sterling Biotech bank loan case

Financial fraud in India

  • 4 min read
  • 3 chapters

Related on Lably

Through Supreme Court of India, Gujarat and United Kingdom

In April 2026, the Supreme Court of India approved a full and final settlement proposed by the promoters. Pursuant to the settlement, the promoters paid a cumulative total of approximately ₹9,800 crore (US$1.0 billion) to the secured lender banks and into the Supreme Court registry. The Court directed that all related criminal, regulatory and civil proceedings be quashed, and the matter was formally closed on 15 April 2026.

Background

Sterling Biotech was founded in the 1990s as a pharmaceutical manufacturer, promoted by Nitin Sandesara, Chetan Sandesara, and Dipesh Patel. The company, listed on the both Indian stock exchanges, was into manufacturing of active pharmaceutical ingredients from their facilities in Gujarat. By the mid-2010s, it had expanded into special economic zones and other ventures under the Sterling Group, including Sterling SEZ and Infrastructure Limited.

The controversy around the company centres on big-ticket loans taken from a consortium of public sector banks led by Andhra Bank (now merged with Union Bank of India). Between 2008 and 2016, the group secured credit facilities exceeding ₹8,100 crore (equivalent to ₹250 billion or US$2.6 billion in 2026) for expansion projects. Investigations revealed that these funds were later diverted through fabricated documents, inflated project costs, and a web of over 249 domestic and 96 offshore shell entities in countries including Nigeria, United Arab Emirates, United Kingdom, British Virgin Islands, United States, Mauritius, Panama, and Barbados.It was also revealed during the investigation that the promoters used employees to incorporate these entities, round-tripped standby letters of credit worth ₹4,500 crore (equivalent to ₹69 billion or US$720 million in 2026), and laundered proceeds via benami transactions.

Early red flags emerged in 2005 when Securities and Exchange Board of India probed share dealings by Sterling Biotech and Sterling International Enterprises Limited (formerly Transworld Infotech Limited) for suspicious trading patterns from August to September 2005. Promoters were accused of concealing benami entities and pressuring regulators to stall the inquiry. By 2017, the loans turned non-performing assets, prompting complaints from banks.

Sign in to keep reading

2 more chapters are free with a Lably account.

More in India